from
Hyderabad-based Bharat Biotech Company on Saturday released the results of the Phase III trial of its Covaxin, in which it has claimed that the vaccine is overall 77.8 per cent effective against corona infection. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant, claims the Bharat Biotech. According to the claim of … Continue reading "Covaxin Phase 3 efficacy data proves 93.4% effective against severe covid signs"
The post Covaxin Phase 3 efficacy data proves 93.4% effective against severe covid signs appeared first on Gulistan News.
https://ift.tt/3AoKF2Avia IFTTT
0 Comments